High Purity Tirzepatide 50mg

High Purity Tirzepatide 50mg — Comprehensive Product Overview Tirzepatide 50 mg is a flagship-format, ultra-high-purity research-grade dual GIP/GLP-1 receptor agonist peptide designed for advanced research programs that demand the highest standards of peptide quality, quantity, and analytical documentation. As the premium dosage in our Tirzepatide portfolio, the 50 mg vial represents the optimal balance of research capacity and purity assurance — delivering sufficient material for comprehensive, multi-endpoint preclinical research programs while maintaining the rigorous ≥99% HPLC purity specification that defines our quality commitment. This is the format of choice for principal investigators conducting definitive studies intended for high-impact publication, grant renewal, patent filing, or regulatory documentation. Tirzepatide (CAS: 2023788-19-2, MW: 4813.5 Da) is the 39-amino acid synthetic peptide amide that has established dual GIP/GLP-1 receptor agonism as a transformative paradigm in incretin biology. The complete molecular sequence — H-Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(AEEA-AEEA-γ-Glu-eicosanedioic acid)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 — embodies a masterclass in peptide engineering: the native GIP backbone serves as a structural scaffold; Aib residues at positions 2 and 13 provide DPP-4 resistance through α-helical stabilization that simultaneously enhances receptor binding affinity; the C20 eicosanedioic acid moiety at Lys20, conjugated through an optimized AEEA-AEEA-γ-Glu linker system, delivers the extended pharmacokinetic profile (albumin binding ≥99.5%, half-life ~5 days in preclinical models) that enables flexible dosing schedules from once-daily to once-weekly; and the overall molecular architecture achieves the imbalanced dual agonism (5-fold GIPR super-agonism with balanced GLP-1R agonism) that produces the synergistic metabolic effects characterizing Tirzepatide pharmacology. The 50 mg format is purpose-built for definitive research: sufficient material for 16-32 animal chronic studies (8-16 weeks) with multi-dose treatment arms, comprehensive serial phenotyping (glucose homeostasis, metabolic cages, body composition), terminal tissue collection for multi-omics analyses, and reserve material for pharmacokinetic verification and independent quality control — all from a single, rigorously characterized production lot. Each vial undergoes an expanded analytical testing cascade beyond our standard protocols, including high-resolution mass spectrometry (HRMS), peptide sequencing (MS/MS), and reverse-phase HPLC purity verification at multiple wavelengths. This product is supplied exclusively for research use only (RUO). Key Features 50 mg flagship research vial — the premium format for definitive, publication-quality preclinical research programs Dual GIP and GLP-1 receptor agonist — the synergistic dual-incretin mechanism that has redefined metabolic research ≥99% HPLC purity — verified at 214 nm with expanded analytical testing including HRMS and MS/MS peptide sequencing Lyophilized powder — 24+ month stability at -20°C; premium packaging for long-term storage integrity DPP-4-resistant molecular design — Aib-stabilized α-helix for sustained in vivo bioactivity Extended-duration albumin-binding pharmacokinetics — C20 diacid moiety for flexible preclinical dosing regimens Expanded analytical documentation — HPLC, HRMS, MS/MS sequencing, AAA, endotoxin, residual solvents, and peptide content Ideal for definitive preclinical studies, grant-funded research programs, IND-enabling pharmacology, and high-impact publication The Science of Tirzepatide: Advanced Mechanisms and Research Frontiers For advanced research programs, the 50 mg Tirzepatide format enables investigation of cutting-edge questions in incretin biology and dual-receptor pharmacology: Signaling bias and functional selectivity — beyond simple agonism, GPCR ligands can differentially activate G-protein versus β-arrestin signaling pathways (biased agonism). Tirzepatide’s signaling profile at GIPR and GLP-1R — the relative engagement of Gαs (cAMP), Gαq (calcium), and β-arrestin (receptor internalization and G-protein-independent signaling) pathways — remains an active area of investigation. The 50 mg quantity supports comprehensive bias profiling using multiple orthogonal assay platforms (BRET biosensors, enzyme complementation, label-free dynamic mass redistribution) to generate robust bias factor calculations. Receptor dimerization and crosstalk — GIPR and GLP-1R are class B GPCRs capable of forming homo- and heterodimers that may alter ligand pharmacology, signaling outputs, and receptor trafficking. Tirzepatide’s ability to simultaneously engage both receptors raises important questions about whether dual agonism promotes or disrupts receptor dimerization, and whether dimerization states influence the synergistic signaling observed in functional assays. Advanced biophysical techniques (BRET/FRET dimerization assays, single-molecule TIRF microscopy, cryo-EM structure determination) require substantial quantities of high-purity ligand — precisely what the 50 mg format provides. Tissue-specific receptor pharmacology — GIPR and GLP-1R expression patterns vary across tissues, species, and disease states. Characterizing Tirzepatide pharmacology in tissue-relevant cellular contexts (primary hepatocytes, adipocytes, islets, neurons, cardiomyocytes, immune cells) requires parallel experiments across multiple cell types, each consuming significant peptide quantities for full dose-response characterization. Central nervous system mechanisms — the relative contributions of peripheral vs. central GIPR and GLP-1R activation to Tirzepatide’s effects on feeding behavior, energy expenditure, and body weight remain incompletely understood. Experiments using BBB-impermeable peptide analogs, conditional receptor knockout models, and site-specific CNS microinjection require precise, high-purity peptide preparations. Immunomodulatory effects — emerging evidence suggests incretin receptors on immune cells may mediate anti-inflammatory effects contributing to metabolic improvements. Investigating Tirzepatide’s effects on adipose tissue macrophage polarization, hepatic Kupffer cell function, and systemic inflammatory cytokine profiles represents a frontier in incretin biology that the 50 mg format is well-suited to explore. Research Applications Tirzepatide 50 mg supports: Definitive chronic preclinical efficacy studies — 8-16 week treatment in 16-32 DIO mice or 8-16 ZDF rats with comprehensive, multi-timepoint phenotyping; Signaling bias and functional selectivity profiling — G-protein vs. β-arrestin bias determination at both GIPR and GLP-1R using multiple assay platforms; Receptor dimerization and structural biology — BRET/FRET dimerization, cryo-EM sample preparation, HDX-MS conformational dynamics; Tissue-specific pharmacology — parallel dose-response characterization in primary cells from multiple tissues; CNS mechanism studies — ICV administration, conditional knockout validation, neuronal activation mapping; Multi-omics tissue analysis — RNA-seq, proteomics, phosphoproteomics, metabolomics, and lipidomics from matched tissue sets; IND-enabling pharmacology — dose-ranging, pharmacokinetic/pharmacodynamic modeling, and preliminary toxicology assessments. Comparative Analysis: Tirzepatide vs. Semaglutide vs. Retatrutide for Definitive Research In definitive, publication-quality studies, the choice of incretin peptide comparator has significant implications for study interpretation: Semaglutide — as the GLP-1R-selective reference standard, Semaglutide is an essential comparator in any study making claims about the specific contributions of GIPR agonism. Head-to-head Tirzepatide vs. Semaglutide comparisons are the gold standard for demonstrating the added value of dual agonism. For definitive studies, researchers should include both compounds at matched doses with comprehensive endpoint analysis. Tirzepatide — the dual agonist is the experimental focus of studies investigating GIP-GLP-1 synergy. The 50 mg format supports the most rigorous experimental designs: adequate statistical power for detecting physiologically meaningful effect sizes, multiple dose levels to characterize dose-response relationships, sufficient duration to capture temporal dynamics, and comprehensive endpoint analysis to fully characterize the metabolic phenotype. Retatrutide — in studies where the research question specifically concerns the role of GCGR agonism, Retatrutide serves as a valuable comparator. However, the triple agonist mechanism introduces complexity that may dilute the scientific focus of GIP-GLP-1-centric studies. For research programs with limited resources, prioritizing Tirzepatide plus Semaglutide as the core comparator pair maximizes scientific return on peptide investment. Disclaimer Research use only. Not FDA-approved for human or veterinary clinical, diagnostic, or therapeutic applications. Qualified researchers at recognized institutions only. Legitimate scientific research use required in compliance with all applicable laws and institutional guidelines. Product Specifications Product Name: Tirzepatide CAS Number: 2023788-19-2 Molecular Formula: C225H348N48O68 Molecular Weight: 4813.5 Da Sequence: H-Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(AEEA-AEEA-γ-Glu-eicosanedioic acid)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 Purity: ≥99% (HPLC, 214 nm) Strength: 50 mg per vial Form: Sterile lyophilized powder Grade: Research Use Only (RUO) Solubility: PBS (pH 7.4), 0.1% acetic acid, DMSO, DMF Storage: Lyophilized: -20°C, desiccated; Reconstituted: aliquot, -20°C or -80°C, avoid freeze-thaw Quality Assurance & Analytical Testing HPLC (214 nm) — ≥99%; HRMS — exact mass confirmation; MS/MS — peptide sequence verification; AAA — compositional analysis; Peptide Content — mass accuracy; Endotoxin (LAL) — quantified; Residual Solvents (GC-HS) — ICH Q3C; Appearance/Solubility/pH — verified; Expanded CoA available upon request. Handling & Storage Guidelines Lyophilized: -20°C, desiccated, 24+ months; Reconstitution: sterile PBS pH 7.4; Post-reconstitution: single-use aliquots, -20°C (4 weeks) or -80°C (6 months); Working solutions: fresh daily; Long-term storage: consider lyophilized powder aliquoting under inert gas for multi-year storage. USA Shipping & Availability Fast USA domestic shipping; Cold-chain insulated packaging; Professional discreet packaging; Available to qualified US research institutions; International shipping for qualified institutions; Premium-format pricing with volume discounts available — contact sales. Why Choose Our High Purity Tirzepatide 50 mg? Flagship format for definitive research — the premium choice for high-impact, publication-quality studies; Expanded analytical testing — HRMS and MS/MS sequencing beyond standard HPLC and ESI-MS; Single-lot integrity for comprehensive research programs; ≥99% HPLC purity with complete documentation; Dual GIP/GLP-1 mechanism for advanced incretin biology research; Trusted by US principal investigators, core facilities, and pharmaceutical R&D groups; Institutional pricing and scheduled delivery available. Advantages and Limitations Advantages: Premium quantity for definitive, adequately powered preclinical studies; Expanded analytical characterization; Single-lot consistency across comprehensive research programs; Supports advanced mechanistic investigations (signaling bias, receptor dimerization, CNS mechanisms); Publication-quality documentation. Limitations: Not for clinical/therapeutic use; IACUC approval required for in vivo protocols; Premium format may exceed requirements for pilot or screening studies; Requires careful storage and aliquot management. Frequently Asked Questions (FAQs) Q: FDA-approved? A: No. Research use only. Q: Who can purchase? A: Qualified researchers at recognized institutions. Q: USA shipping? A: Yes, fast domestic. Q: What is unique about the 50 mg format? A: Expanded analytical testing (HRMS, MS/MS), premium research capacity for definitive studies. Q: Purity? A: ≥99% HPLC, every batch. Q: vs. Semaglutide? A: Dual GIP/GLP-1 vs. GLP-1R-only; Tirzepatide’s dual mechanism produces synergistic metabolic effects. Q: Storage? A: -20°C lyophilized; aliquot reconstituted at -20°C/-80°C. Q: Shelf life? A: 24+ months. Q: Is additional analytical data available? A: Yes, expanded CoA with HRMS and MS/MS available upon request. Q: Bulk/institutional pricing? A: Yes, contact scientific sales. Ordering Information Order at hkpeptidesworldwide.com. For the 50 mg flagship format, we recommend contacting our scientific sales team directly to discuss your research program requirements, arrange institutional pricing, and coordinate delivery scheduling. Purchase orders, credit cards, and wire transfers accepted. HK Peptides Worldwide — your premium partner for advanced incretin research.

Related Research & Resources

Resource	Description
Glp 1 Metabolic Peptides Hub	Complete research overview & methodology hub
High Purity Tirzepatide 50Mg	Related research peptide product
Tirzepatide 10 Mg Research Peptide Vials	Related research peptide product
Glp 1 Peptides Metabolic Research	Latest research insights & methodology

View Complete Research Guide »